How India Exports Epirubicin to the World

Epirubicin has been approved by the U.S. Food and Drug Administration (FDA) for various oncological indications. The initial approval was granted to Mayne Pharma, Inc. on September 15, 2006, under NDA #050807. Subsequently, generic versions have been approved through Abbreviated New Drug Applications (ANDAs). For instance, on September 15, 1999, the FDA approved Epirubicin under the trade name Ellence for the treatment of breast cancer. Additionally, on November 28, 2023, the FDA designated Epirubicin as an orphan drug for the treatment of malignant glioma.

Given the substantial number of active Indian exporters (156) and the competitive average FOB unit price of $9.25, Indian manufacturers are well-positioned to meet the demand for Epirubicin in the U.S. market. However, compliance with FDA regulations, including Good Manufacturing Practices (GMP) and the Drug Supply Chain Security Act (DSCSA), is imperative to ensure market access and maintain product integrity.

In the European Union (EU) and the United Kingdom (UK), Epirubicin is subject to stringent regulatory oversight. Marketing authorization is granted by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must adhere to EU Good Manufacturing Practice (GMP) guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, quality control, and self-inspection. Compliance with these standards is essential for obtaining and maintaining marketing authorization within these jurisdictions.

Epirubicin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The drug is also subject to international pharmacopoeial standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality, safety, and efficacy of Epirubicin across different markets.

In India, Epirubicin is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Epirubicin is not listed under the Drug Price Control Order (DPCO), and thus, its price is not subject to a ceiling. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations and quality standards.

The primary patents for Epirubicin have expired, leading to increased generic competition globally. This competitive landscape has contributed to the average FOB unit price of $9.25 for Indian exports. Manufacturers must focus on maintaining high-quality standards and cost-effective production to remain competitive in the international market.

In July 2025, the FDA designated doxorubicin hydrochloride, a related anthracycline, as an orphan drug for the treatment of osteosarcoma. This development may influence the market dynamics for anthracycline drugs, including Epirubicin.

In December 2025, the EMA recommended restricting the use of dexrazoxane-containing medicines due to safety concerns. (ema.europa.eu) Dexrazoxane is often used in conjunction with anthracyclines like Epirubicin to mitigate cardiotoxicity. This regulatory action may impact the prescribing patterns and demand for Epirubicin in the EU market.

In January 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Epirubicin. This endorsement highlights the drug's continued importance in cancer treatment protocols worldwide.

In February 2026, the NPPA conducted a review of anticancer drug prices but did not impose a ceiling price on Epirubicin, allowing market-driven pricing to prevail.

In March 2026, the DGFT streamlined the export NOC process for pharmaceutical products, reducing the processing time by 20%. This improvement facilitates more efficient export operations for Indian Epirubicin manufacturers.

These developments underscore the dynamic regulatory environment affecting Epirubicin. Manufacturers and exporters must stay informed and adaptable to maintain compliance and competitiveness in the global market.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 70% of India's API and KSM requirements are imported from China, making the supply chain susceptible to disruptions stemming from geopolitical tensions or regulatory changes.

The environmental regulations in India further complicate domestic production. Stringent environmental laws and approval delays make setting up API and KSM manufacturing facilities challenging, leading to higher production costs and longer project timelines. Consequently, many Indian firms prefer importing these materials, perpetuating dependency on Chinese suppliers.

Our proprietary trade data indicates that the top five Indian exporters of Epirubicin account for 78.0% of total exports, with MYLAN LABORATORIES LIMITED alone contributing 21.0%. This high concentration among a few suppliers poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the entire supply chain.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and KSMs. While this initiative has led to the establishment of new manufacturing units, the impact on reducing import dependency and supplier concentration is still evolving.

Recent geopolitical events have further strained the pharmaceutical supply chain. The ongoing conflict in Iran, as of March 2026, has severely disrupted global shipping routes, particularly through the Strait of Hormuz. This chokepoint is vital for global commerce, and its obstruction has led to significant delays and increased costs for goods, including pharmaceuticals exported from India.

Additionally, tensions in the Red Sea and the Suez Canal have compelled shipping companies to reroute vessels around Africa's Cape of Good Hope, adding further delays and expenses. Air cargo options are also under pressure due to closed airspace in several Middle Eastern countries, affecting the timely delivery of high-value goods like Epirubicin.

• Diversify Supplier Base: Encourage the development of additional domestic manufacturers to reduce reliance on a concentrated group of exporters.

• Enhance Domestic Production: Accelerate the implementation and expansion of the PLI scheme to bolster local API and KSM manufacturing capabilities.

• Strengthen Regulatory Frameworks: Streamline environmental and operational approvals to facilitate quicker establishment of manufacturing units, thereby reducing dependency on imports.

• Develop Alternative Shipping Routes: Invest in infrastructure and agreements that provide alternative logistics pathways to mitigate risks associated with geopolitical disruptions.

• Establish Strategic Reserves: Create buffer stocks of critical pharmaceuticals like Epirubicin to cushion against supply chain interruptions.

RISK_LEVEL: HIGH